Critical Comparison: bioAffinity Technologies (NASDAQ:BIAF) versus Protalex (OTCMKTS:PRTX)

bioAffinity Technologies (NASDAQ:BIAF) and Protalex (OTCMKTS:PRTX) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, valuation, profitability, institutional ownership, analyst recommendations, risk and dividends.

Insider & Institutional Ownership

1.6% of bioAffinity Technologies shares are held by institutional investors. 36.4% of bioAffinity Technologies shares are held by insiders. Comparatively, 80.0% of Protalex shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares bioAffinity Technologies and Protalex”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
bioAffinity Technologies	$7.32 million	3.47	-$7.94 million	($0.93)	-2.34
Protalex	N/A	N/A	N/A	N/A	N/A

Protalex has lower revenue, but higher earnings than bioAffinity Technologies.

Profitability

This table compares bioAffinity Technologies and Protalex’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
bioAffinity Technologies	-120.76%	-172.06%	-106.72%
Protalex	N/A	N/A	N/A

Analyst Ratings

This is a breakdown of recent recommendations and price targets for bioAffinity Technologies and Protalex, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
bioAffinity Technologies	0	0	1	0	3.00
Protalex	0	0	0	0	N/A

bioAffinity Technologies presently has a consensus target price of $6.00, indicating a potential upside of 175.23%. Given bioAffinity Technologies’ higher probable upside, equities research analysts plainly believe bioAffinity Technologies is more favorable than Protalex.

About bioAffinity Technologies

bioAffinity Technologies, Inc., a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat lung cancer and other diseases of the lung at the cellular level. The company was incorporated in 2014 and is based in San Antonio, Texas.

About Protalex

Protalex, Inc. focuses on the development of biopharmaceutical drugs for treating autoimmune and inflammatory diseases in the United States. The company targets a range of autoimmune diseases, such as rheumatoid arthritis (RA), immune thrombocytopenia (ITP), psoriasis, myasthenia gravis, chronic idiopathic demyelinating polyneuropathy, and pemphigus. Its lead product candidate is PRTX-100, an immunomodulatory therapy, a highly-purified form of staphylococcal protein A, which is in Phase I/II open-label, dose-escalating study for the treatment of patients with persistent/chronic ITP; and Phase 1b clinical trial for the treatment of RA on methotrexate or leflunomide. The company was founded in 1999 and is based in Florham Park, New Jersey.